Autolus Limited

Ucl Business Plc

Paul Maciocia

Martin Pulé

Shimobi Onuoha

Mathieu Ferrari

Khai Kong

Ben Grimshaw

Ana Margarida Neves

The invention relates to protein-based T-cell receptor knockdown, and its use in T-cell therapies.

Protein-based T-cell receptor knockdown

The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.

Methods

The present invention provides antibodies and polyclonal antibody preparations which bind the intracellular portion of either T-cell receptor constant region 2 (TRBC2) or T-cell receptor constant region 1 (TRBC1). The antibodies can be used to determine whether a T-cell malignancy clonally expresses TRBC1 or TRBC2.

T-cell receptor constant region 1 antibody or T-cell receptor constant region 2 antibody

Method for depleting malignant T-cells

The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TOR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.

Growing community of inventors

London, United Kingdom

Paul Maciocia